Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 21NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 61Daunorubicin 28Specimen Handling 24Etoposide 24Azacitidine 22Decitabine 19Cyclophosphamide 19fludarabine phosphate 18Filgrastim 18Biopsy 18Busulfan 17Idarubicin 16venetoclax 15Peripheral Blood Stem Cell Transplantation 15Mitoxantrone 15Injections 14Vorinostat 12tipifarnib 11Bortezomib 10decitabine and cedazuridine drug combination 9Radiotherapy 9Methotrexate 9alvocidib 8Cyclosporine 8sargramostim 7Melphalan 7Antilymphocyte Serum 7laromustine 6fludarabine 6aldesleukin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myeloid, Acute × Homoharringtonine × Clear all
NCT00030355 2013-03-22

Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡